☆ 4.7 News Item

Sulbactam-durlobactam for Acinetobacter pneumonia

LANCET INFECTIOUS DISEASES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Mortality, Length of Stay, and Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among Elderly Hospitalized Patients in the United States

Richard E. Nelson et al.

Summary: This study analyzed data from the Department of Veterans Affairs in the United States and found that infections due to multidrug-resistant bacteria were associated with high healthcare costs and mortality rates. Efforts to prevent these infections could save a significant number of lives and healthcare resources.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Infectious Diseases

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)

Mical Paul et al.

Summary: These guidelines address the targeted antibiotic treatment of 3GCephRE and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy. Most recommendations are based on low-certainty evidence.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Infectious Diseases

All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies

Thomas P. Lodise et al.

Summary: Pathogen-focused, randomized, controlled trials (PF-RCT) are crucial in the fight against carbapenem-resistant Gram-negative infections. Recent studies have investigated both new and older generic antibiotics in a variety of infections. However, PF-RCTs pose challenges due to heterogeneity in infection types, pathogens, and study design. Interpretation of data is further complicated by the lack of statistical analysis plans and limited power. While new antibiotics showed potential in reducing all-cause mortality in CR Enterobacterales infections, combinations of older generic antibiotics did not demonstrate the same effect in CR Acinetobacter spp. infections. More high-quality PF-RCTs are needed to evaluate the clinical benefit of drug-resistant infections.

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)

添加到收藏夹

Article Medicine, General & Internal

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis

Christopher J. L. Murray et al.

Summary: Antimicrobial resistance (AMR) poses a significant threat to global human health, and this study provides the most comprehensive estimates of AMR burden to date. By estimating deaths and disability-adjusted life-years (DALYs) associated with bacterial AMR in 204 countries and territories in 2019, the study highlights the impact of resistance and the leading pathogen-drug combinations contributing to it.

LANCET (2022)

添加到收藏夹

Article Microbiology

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii

Marco Falcone et al.

Summary: Cefiderocol appears to be a promising therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, with a potential protective effect on 30-day mortality. However, further studies are needed to address the issue of microbiological failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study

Amanda Vivo et al.

Summary: This study investigated the epidemiology of CRAB and CRPA in veterans and found that positive blood cultures and more comorbidities were associated with higher odds of mortality. These findings can guide clinicians to treat patients with these infections in a timely manner to improve outcomes.

BMC INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Microbiology

In Vitro Activity of Sulbactam-Durlobactam against Global Isolates of Acinetobacter baumannii-calcoaceticus Complex Collected from 2016 to 2021

James A. Karlowsky et al.

Summary: Sulbactam-durlobactam demonstrated potent antibacterial activity against geographically diverse clinical isolates of Acinetobacter baumannii-calcoaceticus complex (ABC), including carbapenem-non-susceptible and multidrug-resistant (MDR) isolates.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

添加到收藏夹

Article Infectious Diseases

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

Matteo Bassetti et al.

Summary: The study assessed the efficacy and safety of cefiderocol versus best available therapy in the treatment of patients with carbapenem-resistant Gram-negative infections. Cefiderocol showed similar clinical and microbiological efficacy to best available therapy in this heterogeneous patient population with infections caused by carbapenem-resistant Gram-negative bacteria, suggesting it as an option for the treatment of carbapenem-resistant infections in patients with limited treatment options.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

Richard G. Wunderink et al.

Summary: Cefiderocol was found to be non-inferior to high-dose, extended-infusion meropenem in terms of all-cause mortality on day 14 in patients with Gram-negative nosocomial pneumonia, with similar tolerability. This suggests that cefiderocol is a potential option for the treatment of patients with nosocomial pneumonia, including those caused by multidrug-resistant Gram-negative bacteria.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Microbiology

Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically III Adults in a Phase IV Open-Label Multicenter Study (ACUMIN)

Thomas P. Lodise et al.

Summary: This multicenter study investigated the pharmacokinetics and pharmacokinetic-pharmacodynamic profile of intravenous minocycline in critically ill patients with MDR Acinetobacter baumannii infections. The study found that the dosing regimen of minocycline 200 mg i.v. every 12 hours may not be optimal for patients with MIC values of >1 mg/liter, requiring further clinical confirmation.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

添加到收藏夹

Article Microbiology

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Olexiy Sagan et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Article Microbiology

Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects

Jason D. Lickliter et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

添加到收藏夹

Article Infectious Diseases

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Qiwen Yang et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

添加到收藏夹

Article Infectious Diseases

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul et al.

LANCET INFECTIOUS DISEASES (2018)

添加到收藏夹

Article Microbiology

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii

Thomas F. Durand-Reville et al.

NATURE MICROBIOLOGY (2017)

添加到收藏夹

Review Infectious Diseases

Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review

Jennifer N. Lashinsky et al.

INFECTIOUS DISEASES AND THERAPY (2017)

添加到收藏夹

Article Infectious Diseases

Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections

E. Durante-Mangoni et al.

CLINICAL MICROBIOLOGY AND INFECTION (2016)

添加到收藏夹

Article Microbiology

Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii

William F. Penwell et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

添加到收藏夹

Article Microbiology

Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections

Rujipas Sirijatuphat et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)

添加到收藏夹

Article Immunology

Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

Emanuele Durante-Mangoni et al.

CLINICAL INFECTIOUS DISEASES (2013)

添加到收藏夹

Article Infectious Diseases

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

A. -P. Magiorakos et al.

CLINICAL MICROBIOLOGY AND INFECTION (2012)

添加到收藏夹

Article Immunology

Nephrotoxicity Associated with Intravenous Colistin (Colistimethate Sodium) Treatment at a Tertiary Care Medical Center

Joshua D. Hartzell et al.

CLINICAL INFECTIOUS DISEASES (2009)

添加到收藏夹

Article Urology & Nephrology

Definition and classification of acute kidney injury

John A. Kellum et al.

NEPHRON CLINICAL PRACTICE (2008)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.